Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Published on 08/07/2025 at 18:04 | prnewswire.co.uk
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for differentiated ADCsBigHat's artificial intelligence (AI)/machine learning (ML)-powered antibody design platform, Milliner™ was used to design a highly differentiated antibody that was paired with Synaffix's GlycoConnect™, HydraSpace® and toxSYN® ADC technologies to generate a next-gen ADCView original content:https://www.prnewswire.co.uk/news-releases/lonzas-synaffix-collaborates-with-bighat-biosciences-on-the-development-of-a-machine-learning-designed-adc-302295240.html
en | boerse | 67988354 |
